A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease

Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes

NCT06532682 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment

NCT00663260 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Dapagliflozin in Non-diabetic Stage IV CKD

NCT04794517 ·Status: COMPLETED ·Phase: PHASE2

Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC)

NCT04930549 ·Status: COMPLETED ·Phase: PHASE2

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease

NCT06982079 ·Status: RECRUITING ·Phase: PHASE3

Multi-center, Single Arm, Observational Study to Evaluate the Safety of Dapagliflozin in Type 2 Diabetes Mellitus Patients in China

NCT03156985 ·Status: COMPLETED

A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes

NCT02413398 ·Status: COMPLETED ·Phase: PHASE3

Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria

NCT03190694 ·Status: COMPLETED ·Phase: PHASE2

A Phase 2b Diabetic Kidney Disease Study

NCT04170543 ·Status: COMPLETED ·Phase: PHASE2

GLUcose Transport and REnalPROtection in Chronic Kidney Disease

NCT05998837 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation

NCT06560801 ·Status: RECRUITING ·Phase: PHASE4

Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients

NCT05225077 ·Status: UNKNOWN ·Phase: PHASE4

Renal Mechanism of Action/Splay vs. TmG

NCT00726505 ·Status: TERMINATED ·Phase: PHASE1

Observational Secondary Data Study Describing Treatment With Dapagliflozin Among Adult Chronic Kidney Disease Patients

NCT06203704 ·Status: COMPLETED

Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients

NCT06398977 ·Status: RECRUITING ·Phase: NA

Anemia-Related Outcomes in Patients With CKD Treated With Dapagliflozin

NCT06813222 ·Status: ACTIVE_NOT_RECRUITING

Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients

NCT05735197 ·Status: COMPLETED ·Phase: PHASE4

A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD Patients

NCT06666283 ·Status: RECRUITING ·Phase: PHASE1

The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD

NCT05374291 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3

Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes

NCT00976495 ·Status: COMPLETED ·Phase: PHASE2

Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients with Type 2 Diabetes and CKD

NCT06820567 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Renal Impairment in Type 2 Diabetic Subjects

NCT00554450 ·Status: COMPLETED ·Phase: PHASE1

Effect of Novel Antidiabetic Drug Combined With Angiotensin Receptor/Neprilysin Inhibitor on Urinary Protein

NCT05922852 ·Status: UNKNOWN

Impact of Dapagliflozin on Intestinal Microbiota Composition and on the Metabolites Derived From the Intestinal Microbiota in Non-diabetic Chronic Renal Failure Patients

NCT05965440 ·Status: COMPLETED ·Phase: NA

Effects of Dapagliflozin on Inflammatory Factorslevel and Prognosis in Type 2 Diabetes With Acute Myocardial Infarction

NCT05050500 ·Status: COMPLETED ·Phase: PHASE4